5TH ANNUAL RALLY WILL BE HELD SEPT 22TH, 2012

5th ANNUAL RALLY FOR ALI

IN SEARCH OF A CURE FOR DIABETES

ALL DONATIONS WILL GO TO HARVARD STEM CELL INSTITUTE

PICNIC FOR A CAUSE

KRAUSE’S GROVE, 2 Beach Road, Halfmoon, NY

SATURDAY, SEPTEMBER 21, 2013

1:00 PM TO 6:00 PM ~ RAIN OR SHINE

$30.00 per adult ticket at gate - $20.00 for children under 12

includes donation to Harvard Stem Cell Institute.

5 hour picnic with soda, beer, games, raffles, 50/50, live music

JAMBONE - THE BEAR BONES PROJECT - BLUE HAND LUKE

SPECIAL GUEST APPEARANCE BY AWARD-WINNING IRISH STEP DANCER

GRACE CATHERINE MOMROW (Ali’s cousin)

Abundant food and dessert being served 1:00 p.m. to 5:00 p.m.

Those who wish to join a pre-picnic motorcycle cavalcade around the beautiful Tomhannock Reservoir in Ali’s honor will meet at the Troy Plaza on Hoosick Street at 10:00 A.M. for sign up and the cavalcade will kick off at 11:00 A.M. sharp.

For more info: https://www.facebook.com/Rally4Ali


For Further Information

Contact

For the Run, Wally Urzan

518-368-4826

For the Picnic & Cause

Alison Fisk

AFisk10302@aol.com




Sunday, November 6, 2011


New “braking system” makes stem cell therapy safer

Font size: Decrease font Enlarge font
Share
Houston, TX - Cancer treatment with stem cell transplantation and specially modified immune system components called T-cells can enhance the chance of recovery from diseases such as leukemia or lymphoma.
Now these treatments can be made safer by using a new braking system that almost immediately controls the therapy if things go wrong, said researchers from the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital in a report in the current issue of the New England Journal of Medicine.  
Dr. Malcolm Brenner (www.bcm.edu/genetherapy/faculty-brenner), director of the   Center for Cell and Gene Therapy (www.bcm.edu/genetherapy/), and his colleagues have been developing special anti-tumor cells called T-cells that harness the body’s immune system to fight cancer.  Although they and other investigators have successfully developed ways of targeting these cells to attack cancer, the T-cells can grow in number in the patient and survive many years, which make any side effectssevere, long-lived and often uncontrollable. These treatments would be much safer if researchers could turn the cells off if patients suffered a bad reaction. However, no effective technology existed to rapidly accomplish this outcome.
The Cell and Gene Therapy researchers tested the new safety switch in patients who developed graft versus host disease after they received a stem cell transplant as part of their cancer therapy. During stem cell transplantation, a patient’s own stem cells are eradicated with drugs or radiation.  They then receive an infusion of blood-forming stem cells along with T-cells from a related donor, which help to kill any remaining cancer and to fight infections. However, sometimes the transplanted T-cells attack the patient’s own tissues. The result is graft versus host disease, which is disabling and often fatal. Turning off the T-cells in the transplant would stop the disease. The new treatment accomplishes just that – killing more than 90 percent of the cells within 30 minutes after a single treatment.
To make the safety switch, the researchers introduced into the T-cells a gene called iCasp9, which produces programmed cell death. When the patient receives a specific drug, it joins together two single molecules of iCasp9 (a process called dimerization) and makes it active – rapidly triggering the death of the cell.
“The patients come in with a severe itchy rash all over their bodies,” said Brenner. “We give them the drug and we can literally watch the rash melt away.”
In the study, the investigators gave the genetically modified T-cells to five patients who had received a blood stem cell transplant for relapsed leukemia (a blood cancer). The transplanted T-cells divided in the patients’ blood over time and helped their immunity recover.
Four patients developed the potentially fatal graft versus host disease and received the special activating drug. Within 30 minutes, 90 percent of the T-cells were dead and their graft versus hostdisease began to disappear. The T-cells continued to decrease in number over the next 24 hours and their graft versus host disease went away completely. The small number of T-cells that remained were able to expand and were able to fight infections, but did not cause further graft versus hostdisease
This kind of rapid cellular braking medicine would extend to other T-cell therapies, he said, such as that recently reported in the New England Journal of Medicine [N Engl J Med. 2011 Aug 10. [Epub ahead of print]  (http://www.nejm.org/doi/full/10.1056/NEJMoa1103849), and may ultimately be applicable to other forms of stem cell therapy in general, hastening their safe introduction to the clinic.
Others who took part in this work include Dr. Antonio Di Stasi,  Dr. Siok-Keen Tey, Dr. Gianpietro Dotti, Yuriko Fujita,  Alana Kennedy-Nasser,  Caridad Martinez, Dr. Karin Straath, Enli Liu, April G. Durett, Bambi Grilley, Dr. Hao Liu,  Dr. Conrad R. Cruz,, Dr. Barbara Savoldo, Dr. Adrian P. Gee, Dr. Robert A. Krance, Dr. Helen E. Heslop, Dr. David M. Spencer, and Dr. Cliona M. Rooney, all of BCM and Dr. John Schindler of The University of Texas Southwestern Medical School.
Funding for this work came from the National Institutes of Health, the National Heart, Lung and Blood Institute and the National Cancer Institute. The dimerizing drug was supplied by Bellicum Pharmaceuticals.
Learn more at www.methodisthealth.com. Follow Methodist on Twitter athttp://twitter.com/MethodistHosp and Facebook at http://www.facebook.com/methodisthospital.

Tuesday, November 1, 2011

PERSONAL STEM CELL BANKS

Personal stem cell banks could be staple of future health care
Drs. Xiao-Dong Chen and Qian Wang of The University of Texas Health Science Center San Antonio are members of the research team that discovered a young microenvironment could stimulate old stem cells to expand more rapidly. Credit: UT Health Science Center San Antonio
Old stem cells can be rejuvenated by being placed in a young microenvironment, research from The University of Texas Health Science Center San Antonio shows. This raises the possibility that patients' own stem cells may one day be rescued and banked to treat their age-related diseases.
Stem Cell Breakthrough - Over 2000 Patients Treated for Multiple Diseases. Taking Patients! - Medra.com/StemCell
Stem cells are  that have the potential to convert into bone, muscle,, , and other body cells and tissues. It's no wonder medical science seeks to utilize these versatile cells to restore tissues deteriorated by age, disease or injury.
Older stem cells are not as robust as young ones, however — a challenge to clinicians who seek to use patients' own stem cells to treat age-related diseases.
"The number and quality of those cells decline with age, that is very clear," said Xiao-Dong Chen, M.D., Ph.D., a stem cell researcher at the UT Health ScienceCenter. "And, using the patient's own cells can impact results."
Dr. Chen's team recently made a discovery in mice that, if translated to humans, could solve this predicament.
Old cells expand when grown on a young scaffold of tissue
Dr. Chen suspected that giving stem cells a youthful environment for growth would cause them to regenerate faster. His team extracted mesenchymal stem cells from the bone marrow of 3-month-old mice and 18-month-old mice. The group also obtained extracellular matrix (ECM) from mice of both ages. ECM is a scaffold of connective tissue, such as collagen, which constitutes a majority of the body's structure.
The lab team seeded half of the older stem cells on ECM from the 3-month-old mice and half on ECM from the 18-month-old mice. Likewise, half of the young stem cells were seeded on the young ECM and half were seeded on the old ECM.
Young and old cells showed a 16.1-fold and 17.1-fold expansion, respectively, when grown on ECM from young mice, compared to a 4.1-fold and 3.8-fold expansion when grown on ECM from old mice.
Finding confirmed in rodent implants
Next, under the skin of , Dr. Chen's group implanted artificial scaffolds seeded with stem cells of both ages that had been grown on young or old ECM. These were left to grow for eight weeks. The researchers targeted bone formation. When the implants were removed, the team found that old cells that had been grown on a young ECM produced just as much bone as young cells, while old cells grown on an old ECM produced no bone. The results were published in the FASEB Journal earlier this year.
"If this research transfers successfully to clinical application in humans, we could establish personal stem cell banks," Dr. Chen said. "We would collect a small number of older stem cells from patients, put those into our young microenvironment to rescue them — increasing their number and quality — then deliver them back into the patient."
This stem cell rescue and infusion could be done as often as disease treatment requires it, he said. The next step is to repeat the study in human  and ECM.
Dr. Chen, an associate professor of comprehensive dentistry in the Health Science Center Dental School, discussed the finding at the Strategies for Engineered Negligible Senescence conference (SENS,http://www.sens.org/conferences/sens5) held at Queens' College in Cambridge, U.K.
Provided by University of Texas Health Science Center at San Antonio

Friday, October 21, 2011


Stem cells needed from ethnic communities

 

Registration takes only a cheek swab is all that is needed to register and donation is often as simple as giving blood

 
 
 
Ethnically diverse stem cell donors are needed to help Canadian patients with cancer and blood diseases such as leukemia.
When University of B.C. biochemistry student Bonita Ma heard about the need, she and some other students decided their campus would be a good place to attract such donors, who need to be aged between 17 and 50. UBC will hold a donor drive on October 26 from 10 a.m. to 7 p.m. at the student union building.
The campaign, which is happening at universities throughout the country, is called Get Swabbed because getting a cheek swab is all that’s required to register to become a donor. The saliva is tested for DNA and put on a national registry which can then be searched by doctors. If a donor is found to be a match for a patient in need, the donation process is often as simple as collecting blood, said Olga Pazukha, spokeswoman for the OneMatch Stem Cell and Marrow Network, which recruits donors and coordinates collection and delivery of stem cells.
About 30 per cent of the time a donor match can be found within a patient’s family, but when this is not possible, patients are matched to donors through specific genetic markers that make them unique. This is where ethnicity becomes important, Pazukha said.
“A lot of those things would come from their ethnic background. So, say if I’m of South Asian descent and I need a match, my potential donor would also be someone from the South Asian community.”
There are more than 300,000 potential donors registered throughout Canada, but 77 per cent of them are of European descent, while 23 per cent are from other ethnic backgrounds, Pazukha said.
“It’s really important to get a very diverse donor pool so that we are able to help all of the patients that are looking for matches in Canada.”
Ma, who is of Chinese descent, said many people from that community don’t realize how easy the donation process is and have a misperception that it is very painful. OneMatch is reaching out to ethnic communities across Canada to educate people about the need for donors and the relatively simple nature of the process, Pazukha said.
There are 957 patients across the country in need of a match.


Read more:http://www.vancouversun.com/health/Stem+cells+needed+from+ethnic+communities/5582967/story.html#ixzz1bRp2xonl

Monday, October 17, 2011


Stem cell breakthrough could bring cure for genetic diseases

By Laura Shin | October 16, 2011, 7:16 PM PDT
One of the most common genetic mutations can lead to cirrhosis of the liver, and the only cure is a liver transplant, which creates its own problems: The recipient must, for the rest of his/her life, take drugs that prevent organ rejection.
But scientists have now achieved a breakthrough that means that patients with genetic diseases could someday be treated with their own cells.
The technique combines two of the most powerful medical technologies — stem cell technology and gene therapy — and could usher in a new era of personalized therapies for genetic disorders.
While the achievement marks an important step, years of trials are needed before any such treatments are available for humans.

How the therapy works

Currently, people with genetic diseases cannot be treated with their own stem cells, because those cells would also contain the genetic mutation.
But scientists at the Wellcome Trust Sanger Institute and the University of Cambridge took skin cells from a patient with metabolic liver disease, and fixed the mutation in them by excising the incorrect DNA letter and inserting the correct one.
They then turned those skin cells into liver cells that one of the lead researchers, David Lomas, said “functioned beautifully with normal secretion and function.”
They inserted the new liver cells into mice, and six weeks later, the cells were still working correctly.
Lomas told the BBC that the technique was “ridiculously hard.” He and his colleagues published their results in Nature.

Remaining hurdles

While the technique is extremely promising, a number of safety concerns remain before it can be widely used.
First, stem cells cultured in labs tend to develop mutations. In this experiment, the researchers compared the corrected line to the genome of the original skin cells and found a few extra mutations in the corrected cell lines. (However, there were many fewer mutations in the corrected lines than in the stem cells that had not been corrected.)
Also, the scientists can always screen each stem cell line to choose the ones with the fewest extra mutations.
Another concern is the cost of developing personalized therapies, although this technique could also save money because it obviates the need for a lifetime anti-organ rejection drugs.
The scientists are now aiming to work with a pharmaceutical company to eventually hold trials in people.
Photo: Human embryonice stem cells (Nissim Benvenisty/Wikimedia Commons)

Wednesday, October 12, 2011


Seeking Superior Stem Cells

October 12, 2011
Seeking Superior Stem Cells
New technique produces one hundred-fold increase in efficiency in reprogramming human cells
Researchers from the Wellcome Trust Sanger Institute have recently announced a new technique to reprogramme human cells, such as skin cells, into stem cells. Their process increases the efficiency of cell reprogramming by one hundred-fold and generates cells of a higher quality at a faster rate.
Until now cells have been reprogrammed using four specific regulatory proteins. By adding two further regulatory factors, Liu and co-workers brought about a dramatic improvement in the efficiency of reprogramming and the robustness of stem cell development. The new streamlined process produces cells that can grow more easily.
"This research is a milestone in human stem cells," explains Wei Wang, first author on the research from the Wellcome Trust Sanger Institute. "Our technique provides a foundation to unlock the full potential of stem cells."
Stem cells are unspecialized cells that are able to renew themselves through cell division and can be induced to become functional tissue- or organ-specific cells. It is hoped that stem cells will be used to replace dying or damaged cells with healthy, functional cells. This could have wide-ranging uses in medicine such as organ replacement, bone replacement and treatment of neurodegenerative diseases.
With more than 20 years of research, gold standard stem cells are derived from mice, largely because they are easy to work with and provide accurate and reproducible results. The team's aim was to develop human cells of equivalent quality to mouse stem cells.
"The reprogrammed cells developed by our team have proved to have the same capabilities as mouse stem cells," states Pentao Liu, senior author from the Sanger Institute. "Our approach will enable researchers to easily engineer and reprogramme human stem cells to generate cell types for cell replacement therapies in humans."
Retinoic acid receptor gamma (RAR-Y) and liver receptor homolog (Lrh-1), the additional regulatory factors used by Liu and co-workers, were introduced into the skin cells along with the four other regulatory proteins. The team's technology produced reprogrammed cells after just four days, compared to the seven days required for the four-protein approach. Key indicators of successfully reprogrammed cells, Oct4 and Rex-1 genes, were seen to be switched on much faster in a much higher number of cells, demonstrating increased efficiency in reprogramming.
"This is the most promising and exciting development in our attempt to develop human stem cells that lend themselves in practical applications. It bears comparison to other technologies as it is simple, robust and reliable," says Allan Bradley, Senior Group Leader and Director of Emeritus at the Sanger Institute.
About The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
About The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
SOURCE: Wellcome Trust Sanger Institute